Skip to content

Evaluation of clinical efficacy and safety of herbs of rich-Iodine for Graves' Hyperthyroidism (the HIGHT trial) patients with oral ATDs intolerant

Evaluation of clinical efficacy and safety of herbs of rich-Iodine for Graves' Hyperthyroidism (the HIGHT trial) patients with oral ATDs intolerant

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032706
Enrollment
Unknown
Registered
2020-05-07
Start date
2020-08-01
Completion date
Unknown
Last updated
2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves' disease

Interventions

Sponsors

Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Diagnosis criteria (Guidelines for Clinical Diagnosis and Treatment of thyroid disease in 2007, CSE) 1. Clinical manifestations of hyperthyroidism; 2. The presence of diffuse goiter; 3. The suppressed serum TSH and elevated thyroid hormones (FT4 and FT3); 4. The presence of exophthalmos; 5. The presence of Pretibial myxedema(PM); 6. The presence of TSH-Receptor Antibodies (TRAb/TSAB). TCM symptoms criteria (Chinese New Medicine Treatment of Diabetes Clinical Research Guiding Principle) yin deficiency with heat. Inclusion criteria 1. Adults over 18 years to under 70 years of age; 2. Fulfill GD diagnostic criteria; 3. Intolerance to high-dose therapy with Methimazole (MMI) or Propylthiouracile (PTU), and refuse thyroidectomy or radiotherapy (I131) RAI; 4. Fulfill TCM diagnostic criteria; 5. Those who have voluntarily signed a written consent form approved by the IRB after sufficient explanation of this study.

Exclusion criteria

Exclusion criteria: 1. Hyperthyroidism crisis; 2. Symptomatic compression or large goiter; 3. Subjects who allergy to the components in TCM and/or placebo; 4. Those who have thiocarbamides-associated major side effects including of severe hepatitis(elevation of AST or ALT more than double the normal upper limit), agranulocytosis (neutrophil count < 500/mL), severe exfoliative dermatitis; 5. Women who are pregnant or lactating, or preparing for pregnancy and lactating women; 6. Subjects with a history of alcohol abuse, drug abuse, or mental diseases; 7. Those who are in seriously unstable medical condition, such as cardiovascular disease, cerebrovascular disease, hepatobiliary disease, renal disease or problems in the urinary reproductive system, or neoplasms, or whose treatment with any medication potentially influencing thyroid function (IFN-gama, amiodarone, lithium, corticosteroids, etc.); 8. Subjects who have taken other clinical trial drugs within 3 months; 9. Subjects who are thought to be inappropriate for this study.

Design outcomes

Primary

MeasureTime frame
thyroid function;

Secondary

MeasureTime frame
TRAb, TgAb, TPOAb;Thyroid Imaging (US.);Evaluation of TCM Syndrome;Quality of life (QoL);General physical examination;Pregnancy Test;Demographic information;Record of medical history;

Countries

China

Contacts

Public ContactGao Tianshu

Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

gaotianshu67@163.com+86 18102459018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026